Portfolio News
Sofinnova MD Start
ELSAN partners with MD Start III to accelerate medtech innovation
This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
Related Strategy
MD StartRelated Deal lead
Anne OsdoitThis collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
June 25, 2020 - PARIS, France -
ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinnova MD START III acceleration fund. Through this partnership, ELSAN becomes an investor in the acceleration fund co-created and managed by Sofinnova Partners, a leading European venture capital firm, and offers its healthcare practitioners the means to accelerate the development of their medical device innovations for the benefit of patients.
"We are delighted that ELSAN is joining Sofinnova MD Start III as a community of clinical investigators and experts," commented Anne Osdoit, Partner at Sofinnova Partners.
Related News
Qorium Becomes Reyva as Cultivated Leather Company Moves Towards Commercial Scale
Purespring Therapeutics advances kidney-targeted gene therapy PS-003 towards the clinic in X-linked Alport Syndrome
DMC secures $18M to expand health ingredients business
CorWave completes enrollment in feasibility study and presents first clinical data on adaptive support with its Wave Membrane LVAD
Muna Therapeutics announces positive Phase 1 results supporting potential of oral small-molecule TREM2 Modulator in Alzheimer’s disease